{
  "source": "PA-Med-Nec-Empaveli.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2244-6\nProgram Prior Authorization/Medical Necessity\nMedication Empaveli® (pegcetacoplan)\nP&T Approval Date 7/2021, 7/2022, 8/2023, 2/2024, 4/2024, 4/2025\nEffective Date 7/1/2025\n1. Background\nEmpaveli (pegcetacoplan) is a complement inhibitor indicated for the treatment of adult\npatients with paroxysmal nocturnal hemoglobinuria (PNH).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Empaveli will be approved based on all of the following criteria:\na. Submission of medical records (e.g., chart notes, laboratory values, etc.)\ndocumenting the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) as\nconfirmed by both of the following:\n(1) Flow cytometry analysis confirming presence of PNH clones\n-AND-\n(2) Laboratory results, signs, and/or symptoms attributed to PNH (e.g., abdominal\npain, anemia, dyspnea, extreme fatigue, smooth muscle dystonia,\nunexplained/unusual thrombosis, hemolysis/hemoglobinuria, kidney disease,\npulmonary hypertension, etc.)\n-AND-\nb. One of the following:\n(1) Patient will not be prescribed Empaveli in combination with another\ncomplement inhibitor used for the treatment of PNH (e.g., Bkemv, Fabhalta,\nPiaSky, Soliris, Ultomiris)\n-OR-\n(2) Patient is currently receiving another complement inhibitor (e.g., Bkemv,\nFabhalta, PiaSky, Soliris, Ultomiris) which will be discontinued and Empaveli\nwill be initiated in accordance with the United States Food and Drug\nAdministration approved labeling\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n1\nc. Prescribed by, or in consultation with one of the following:\n(1) Hematologist\n(2) Oncologist\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Empaveli will be approved based on all of the following criteria:\na. Documentation of positive clinical response to Empaveli therapy (e.g., increased or\nstabilization of hemoglobin levels, reduction in transfusions, improvement in\nhemolysis, decrease in LDH, increased reticulocyte count",
    "ositive clinical response to Empaveli therapy (e.g., increased or\nstabilization of hemoglobin levels, reduction in transfusions, improvement in\nhemolysis, decrease in LDH, increased reticulocyte count, etc.)\n-AND-\nb. Patient is not receiving Empaveli in combination with another complement inhibitor\nused for the treatment of PNH (e.g., Bkemv, Fabhalta, PiaSky, Soliris, Ultomiris)\n-AND-\nc. Prescribed by, or in consultation with one of the following:\n(1) Hematologist\n(2) Oncologist\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Empaveli [package insert], Waltham, MA: Apellis Pharmaceuticals, Inc.; September 2023.\n2. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal\nhemoglobinuria. Blood. 2005 Dec 1; 106(12): 3699–3709.\n3. Devalet B, Mullier F, Chatelain B, et al. Pathophysiology, diagnosis, and treatment of\nparoxysmal nocturnal hemoglobinuria: a review. Eur J Haematol. 2015 Sep;95(3):190-8.\n© 2025 UnitedHealthcare Services Inc.\n2\n4. Sutherland DR, Keeney M, Illingworth A. Practical guidelines for the high-sensitivity\ndetection and monitoring of paroxysmal nocturnal hemoglobinuria clones by flow\ncytometry. Cytometry B Clin Cytom. 2012 Jul;82(4):195-208.\n5. Röth A, Maciejewski J, Nishimura JI, et al. Screening and diagnostic clinical algorithm for\nparoxysmal nocturnal hemoglobinuria: Expert consensus. Eur J Haematol. 2018\nJul;101(1):3-11.\nProgram Prior Authorization/Medica",
    " J, Nishimura JI, et al. Screening and diagnostic clinical algorithm for\nparoxysmal nocturnal hemoglobinuria: Expert consensus. Eur J Haematol. 2018\nJul;101(1):3-11.\nProgram Prior Authorization/Medical Necessity - Empaveli® (pegcetacoplan)\nChange Control\n7/2021 New program\n7/2022 Annual review with no changes to coverage criteria. Updated citations\nin background and coverage criteria.\n8/2023 Annual review. Updated references.\n2/2024 Added Fabhalta to list of examples of other complement inhibitors used\nfor the treatment of PNH. Revised initial authorization to 12 months.\nIncluded criteria for therapeutic duplication. Updated references.\n4/2024 Simplified criteria language for converting to new complement inhibitor\ntherapy.\n4/2025 Annual review. No changes to coverage criteria. Updated examples of\nalternate complement inhibitors.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}